| Current Price | $113.75 | Mkt Cap | $10.4B |
|---|---|---|---|
| Open | $113.00 | P/E Ratio | 489.35 |
| Prev. Close | $113.08 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $111.18 - $114.34 | Volume | 690,778 |
| 52-Wk Range | $67.10 - $116.06 | Avg. Daily Vol. | 751,813 |
Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.
| Current Price | $113.75 | Mkt Cap | $10.4B |
|---|---|---|---|
| Open | $113.00 | P/E Ratio | 489.35 |
| Prev. Close | $113.08 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $111.18 - $114.34 | Volume | 690,778 |
| 52-Wk Range | $67.10 - $116.06 | Avg. Daily Vol. | 751,813 |
The best Bull and Bear pitches based on recency and number of recommendations.
Neurocrine has been turning in solid pipeline progress for several years now but they haven't had much success holding gains in the share price. Now that the phase III trial of elagolix is in progress I expect at least a year before all 875 patients… More
Read the most recent pitches from players about NBIX.
Recs
mrbill6
(< 20)
Submitted: 11/18/2019 4:26:54 PM :
Start Price:
$113.30
NASDAQ:NBIX Score:
+1.06
Zacks likes it short term
Recs
theomegafox
(< 20)
Submitted: 10/26/2019 3:31:30 AM :
Start Price:
$98.00
NASDAQ:NBIX Score:
+13.63
Outperform everybody every day.
Recs
Bigsef77
(68.02)
Submitted: 1/8/2019 2:52:48 PM :
Start Price:
$53.71
NASDAQ:NBIX Score:
+82.45
Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
[Zacks]
Zacks Equity Research
,Zacks•January 7, 2019
Neurocrine Biosciences, Inc. NBIX provided preliminary sales guidance for Ingrezza pertaining to the fourth quarter of 2018 and the full year along with an update on its pipeline candidates.
2018 Preliminary Results
Based on unaudited financial results, Neurocrine expects Ingrezza sales for the full year to be approximately $409 million, reflecting a staggering increase of 250.8% from the prior-year level. The company estimates Ingrezza for the final quarter to be approximately $130 million, which is also significantly higher than the year-earlier level. The company guided preliminary total prescriptions for Ingrezza to be approximately 22,900 and 71,500 for the fourth quarter and full year, respectively.
Ingrezza is Neurocrine’s only marketed drug, which received an FDA approval in 2017. It is the first medicine approved in the United States for treating adults with tardive dyskinesia (TD). The drug is also being investigated for Tourette syndrome and has been granted an Orphan Drug Designation by the FDA for the same.
Shares of Neurocrine have lost 4% in the past year, narrower than the industry’s decline of 17.8%.
Find the members with the highest scoring picks in NBIX.
gsm1999 (78.38) Score: +4,674.04
The Score Leader is the player with the highest score across all their picks in NBIX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| gsm1999 | 78.38 | 3/8/2010 |
|
5Y | $2.30 | +4,845.65% | +171.61% | +4,674.04 | 0 Comment | |
| awsumrocker | 87.94 | 3/10/2010 |
|
3M | $2.35 | +4,740.43% | +171.02% | +4,569.41 | 0 Comment | |
| stockamuteur | 68.82 | 4/8/2010 |
|
5Y | $2.57 | +4,326.07% | +163.11% | +4,162.96 | 0 Comment | |
| Tadpole85 | 84.24 | 1/5/2010 |
|
1Y | $2.68 | +4,144.40% | +174.01% | +3,970.40 | 0 Comment | |
| borcobob | 74.57 | 12/28/2009 |
|
3Y | $2.82 | +3,933.69% | +174.88% | +3,758.81 | 0 Comment | |
| royeknox | 83.84 | 8/10/2009 |
|
5Y | $3.03 | +3,654.13% | +209.62% | +3,444.50 | 0 Comment | |
| MicroMikey | 49.74 | 4/15/2010 |
|
5Y | $3.10 | +3,569.35% | +156.50% | +3,412.85 | 0 Comment | |
| MicroOptions | 56.38 | 4/15/2010 |
|
5Y | $3.10 | +3,569.35% | +156.50% | +3,412.85 | 0 Comment | |
| minifesto | 79.79 | 1/2/2009 |
|
3Y | $3.21 | +3,443.61% | +249.19% | +3,194.42 | 0 Comment | |
|
foolshand | < 20 | 7/27/2009 |
|
3W | $3.25 | +3,400.00% | +218.55% | +3,181.45 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
